Calendar 2008-2009
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Proofs for the Working Engineer
Research Collection Doctoral Thesis Proofs for the working engineer Author(s): Mehta, Farhad Dinshaw Publication Date: 2008 Permanent Link: https://doi.org/10.3929/ethz-a-005635243 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH NO. 17671 Proofs for the Working Engineer A dissertation submitted to ETH ZURICH for the degree of Doctor of Sciences presented by Farhad Dinshaw Mehta Master of Science, Technische Universit¨atM¨unchen Bachelor of Technology, Indian Institute of Technology Delhi born 11.01.1980 citizen of India accepted on the recommendation of Prof. Jean-Raymond Abrial Prof. Peter M¨uller Prof. Cliff Jones 2008 Abstract Over the last couple of decades the advantages of including formal proof within the development process for computer based systems has become in- creasingly clear. This has lead to a plethora of logics and proof tools that propose to fulfill this need. Nevertheless, the inclusion of theorem proving within the development process, even in domains where clear benefits can be expected, is rather an exception than the rule. One of the main goals of the formal methods endeavour is to bring the ac- tivity of formal theorem proving closer to the engineer developing computer based systems. This thesis makes some important practical contributions towards realising this goal. It hopes to shows that proper tool support can not only ease theorem proving, but also strenghten its role as a design aid. It shows that it is feasible to integrate interactive proof within a reactive development environment for formal systems. -
Universidad Autónoma De Madrid
UNIVERSIDAD AUTÓNOMA DE MADRID DEPARTAMENTO DE BIOLOGÍA MOLECULAR Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Madrid, 2015 DEPARTAMENTO DE BIOLOGÍA MOLECULAR FACULTAD DE CIENCIAS UNIVERSIDAD AUTÓNOMA DE MADRID Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Licenciatura en Biología Molecular y Fisiología Director de Tesis: Prof. Christopher Heeschen, M.D. PhD Centro de células madre en el cáncer y el envejecimiento Barts Instituto de Cancer (BCI) This thesis, submitted for the degree of Doctor of Philosophy at the Universidad Autónoma de Madrid, has been completed in the Stem Cells & Cancer Group at the Spanish National Cancer Research Centre (CNIO) and Centre for Stem Cells in Cancer and Ageing, Barts Cancer Instutute (BCI) under the supervision of Prof. Dr. Christopher Heeschen. Dedicated to my parents, my sister Ivana and my friends who always supported me. ACKNOWLEDGEMENTS It is strange to look back in time and see myself entering true the door of CNIO my first day in Christopher’s laboratory back in October 2010. For some maybe little and for other’s so much. Thank you Christopher for replaying to my email and opening me the door of your lab! It was just a start of an incredible journey that led me where I am now, and that will mark my next trails to run. So many people I need to mention and say thanks for their unconditional help and support. Enza thank you for accepting me as your student and for being patient with me. I will never forget how you would always tell me to think why I am doing things. -
University of Toronto University-Wide Impact Presentation
UNIVERSITY OF TORONTO UNIVERSITY-WIDE IMPACT PRESENTATION INTRO: .......................................................................................... 2 SECTION 1: GLOBAL FOOTPRINT .............................................. 3 SECTION 2: INNOVATION AND IMPACT .................................... 15 SECTION 3: EXCELLENCE AND LEADERSHIP IN SOCIETY ..... 31 Text is not editable on animation slides. Updated May 2021 ON-SCREEN IMAGE SPEAKER’S NOTES BEGINNING OF PRESENTATION [Good afternoon]. My name is [X], and I serve as [X] at the University of Toronto. Thank you for joining us [today]. [Today] I would like to take you through a presentation that speaks to the crucial role that U of T is honoured to play in our communities and our world. U of T is a world-leading university with three campuses in the Greater Toronto Area. We provide students with a comprehensive global education, produce life-changing research, and promote economic growth and social progress in our communities. I’m going to cover three aspects: • U of T’s Global Footprint • U of T’s Innovation and Impact • U of T’s Excellence and Leadership in Society Since its very early days, U of T has been fortunate to have forged connections with institutions around the world and to have welcomed faculty and students from elsewhere to become part of the U of T community. Today, U of T’s global footprint is significant. 2 SECTION 1 GLOBAL FOOTPRINT 3 ON-SCREEN IMAGE SPEAKER’S NOTES We are immensely proud of our worldwide alumni community. Over 630,000 U of T alumni live, work and contribute to civil society in more than 190 countries and territories. Few universities in the world can rival the cultural diversity of our student population. -
Download Program Guide
2011 C. elegans Meeting Organizing Committee Co-chairs: Oliver Hobert Columbia University Meera Sundaram University of Pennsylvania Organizing Committee: Raffi Aroian University of California, San Diego Ikue Mori Nagoya University Jean-Louis Bessereau INSERM Benjamin Podbilewicz Technion Israel Institute of Keith Blackwell Harvard Medical School Technology Andrew Chisholm University of California, San Diego Valerie Reinke Yale University Barbara Conradt Dartmouth Medical School Janet Richmond University of Illinois, Chicago Marie Anne Felix CNRS-Institut Jacques Monod Ann Rougvie University of Minnesota David Greenstein University of Minnesota Shai Shaham Rockefeller University Alla Grishok Columbia University Ahna Skop University of Wisconsin, Madison Craig Hunter Harvard University Ralf Sommer Max-Planck Institute for Bill Kelly Emory University Developmental Biology, Tuebingen Ed Kipreos University of Georgia Asako Sugimoto RIKEN, Kobe Todd Lamitina University of Pennsylvania Heidi Tissenbaum University of Massachusetts Chris Li City College of New York Medical School Sponsored by The Genetics Society of America 9650 Rockville Pike, Bethesda, MD 20814-3998 telephone: (301) 634-7300 fax: (301) 634-7079 e-mail: [email protected] Web site: http:/www.genetics-gsa.org Front cover design courtesy of Ahna Skop 1 Table of Contents Schedule of All Events.....................................................................................................................4 Maps University of California, Los Angeles, Campus .....................................................................7 -
PS CV Comp 050917
CURRICULUM VITAE NAME: Pamela Mary Stanley (nee Fetherstonhaugh) Lab Homepage http://www.einstein.yu.edu/departments/cellbiology/faculty/stanley/home/ NATIONALITY: Australian/American EDUCATION: l965-l967 Bachelor of Science University of Melbourne, Australia Majored in Biochemistry and Microbiology l968 B. Sc. Hons., Walter and Eliza Hall Institute, Melbourne, Australia Commonwealth Post-graduate Award Advisor: Gordon L. Ada Thesis: Tolerance to Foreign Erythrocytes Using Antigen-Containing Extracts of the Erythrocyte Membrane. l969-l972 Research for degree of Doctor of Philosophy in the Department of Microbiology, University of Melbourne, Australia Commonwealth Post-graduate Award Advisor: Professor David O. White Thesis: Influenza Virus Proteins l972-l975 Postdoctoral Fellow of the Medical Research Council of Canada in the Department of Medical Genetics, University of Toronto, Canada Advisor: Dr. Louis Siminovitch Postdoctoral Fellowship from the Medical Research Council of Canada Topic: The Isolation and Characterization of Lectin Resistant Chinese Hamster Ovary Cells. POSITIONS HELD: l976 Research Associate Department of Medical Genetics University of Toronto Toronto, Ontario, Canada l977-1982 Assistant Professor Dept. of Cell Biology Albert Einstein College of Medicine Bronx, New York 1982-1986 Associate Professor Dept. of Cell Biology Albert Einstein College of Medicine Bronx, New York 1986 Professor Department of Cell Biology Albert Einstein College of Medicine Bronx, New York 1994-2007 Director Training Program in Cell & Molecular Biology, Biochemistry & Genetics, NIGMS 1 1988-2012 Program leader Membrane Molecular Biology Albert Einstein Cancer Center 2002- Associate Director for Laboratory Research Albert Einstein NCI Cancer Center 2007- Horace W. Goldsmith Foundation Chair. HONORS: Dunlop Prize for First Place in Biochemistry (1966 and 1967) Aust. -
Exploring Nsr100/SRRM4 As a Therapeutic Target for Autism Spectrum Disorder in Mice
Exploring nSR100/SRRM4 as a therapeutic target for autism spectrum disorder in mice by Juli Wang A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Molecular Genetics University of Toronto © Copyright by Juli Wang, 2019 I Exploring nSR100/SRRM4 as a Therapeutic Target for ASD in Mice Juli Wang Master of Science Department of Molecular Genetics University of Toronto 2019 Abstract Misregulation of nSR100 and its target microexons are common in a large proportion of ASD patients and cause ASD-associated features in mice. This thesis explores nSR100 and its target splicing program as a potential therapeutic target using a conditional knockout allele, nSR100GT. I show that nSR100 protein is effectively depleted in the cortical regions of nSR100GT mutant mice at E17.5, E18.5, and P2 stages, which correlates with phenotypes overlapping with all core behavioral domains of ASD. I show that tamoxifen-mediated rescue in prenatal nSR100GT animals restores nSR100 protein and microexon inclusion levels comparable to those observed in wildtype mice. Collectively my thesis research shows that the nSR100GT mouse strain holds the promise for examining phenotypic effects of nSR100 reactivation in ASD-like mice at different developmental stages, and complimentary models are also to be considered for investigating the therapeutic potential of targeting nSR100 in the context of ASD. II Acknowledgments I wholeheartedly thank for the tremendous support and educational experiences I have received from my mentors, -
Refereed Publications (A = Article, C = Communication, R = Review)
Curriculum Vitae: Douglas W. Stephan FRSC, FRS Current Address Department of Chemistry, University of Toronto, 80 St. George St. Toronto, ON, M5S3H6 [email protected]; [email protected] Phone: 416-946-3294; Cell: 647-339-3568; Admin. Asst: Shanna Pritchard 416-978-8940, [email protected] webpage: http://www.chem.utoronto.ca/staff/DSTEPHAN Home Address 47 St. Clair Ave. W., Suite 302, Toronto, ON. M4V 3A5; Home: 416-619-5901 Personal Born in Hamilton, Ontario, CANADA July 27 1953, married (Dianne L. Gunn) two adult children (David and Kathryn) Citizenship Canadian Education Ph.D 1980 (University of Western Ontario), B.Sc. 1976 (McMaster University, summa cum laude) Positions Held 2018-present University Professor, University of Toronto 2008-2018 Professor, University of Toronto 2016-2019 Chair, Editorial Board of Chemical Society Reviews 2016-2018 Einstein Visiting Fellow, TU Berlin. 2011-2017 Associate Editor, Chemical Society Reviews 2006 (Oct) International Research Guest Professor, WW-Universitaet Muenster 2008-2021 Canada Research Chair in Catalysis and New Materials (UToronto) 2005-2007 Canada Research Chair in Catalysis and New Materials (UWindsor) 2003-2006 Head, Department of Chemistry & Biochemistry 2002-2007 University Professor, University of Windsor 2002-2003 Humboldt Senior Awardee, WW-Universitaet Muenster 2001-2006 NSERC/NOVA Chemicals Corporation Industrial Research Chair 1995 DAAD Visiting Scientist, Muenster, Germany (declined) 1995 NSERC/DFG Visiting Scientist, WW-Universitaet Muenster. 1992-2002 -
GLYCO 21 XXI International Symposium on Glycoconjugates
GLYCO 21 XXI International Symposium on Glycoconjugates Abstracts August 21-26, 2011 Vienna, Austria Glycoconj J (2011) 28: 197–36 9 Organising Committee Erika Staudacher (Austria) Leopold März (Austria) Günter Allmaier (Austria) Lothar Brecker (Austria) Josef Glössl (Austria) Hanspeter Kählig (Austria) Paul Kosma (Austria) Lukas Mach (Austria) Paul Messner (Austria) Walther Schmid (Austria) Igor Tvaroška (Slovakia) Reinhard Vlasak (Austria) Iain Wilson (Austria) Scientifi c Program Committee Iain Wilson (Austria) Paul Messner (Austria) Günter Allmaier (Austria) Reginald Bittner (Austria) Paul Kosma (Austria) Eva Stöger (Austria) Graham Warren (Austria) John Hanover (USA; nominated by the Society for Glycobiology) Kelly ten Hagen (USA; nominated by the Society for Glycobiology) supported in abstract selection by Michael Duchêne (Austria) Catherine Merry (UK) Tadashi Suzuki (Japan) Abstracts of the 21st International Symposium on Glycoconjugates The International Glycoconjugate Organisation Gerald W. Hart, President Leopold März, President-elect Paul Gleeson, Immediate Past-president Sandro Sonnino, Secretary Thierry Hennet, Treasurer National Representatives Pedro Bonay (Spain) to replace Angelo Reglero Nicolai Bovin (Russia) Jin Won Cho (Korea) Henrik Clausen (Denmark) Anne Dell (UK) Jukka Finne (Finland) Paul Gleeson (Australia) Jianxin Gu (China) Gerald Hart (USA) Thierry Hennet (Switzerland) Jim Jamieson (Canada) Gordan Lauc (Croatia) Hakon Leffl er (Sweden) Jean-Claude Michalski (France) Werner Reutter (Germany) Sandro Sonnino (Italy) Avadhesha Surolia (India) Ken Kitajima (Japan) Maciej Ugorski (Poland) Johannes F.G. Vliegenthart (The Netherlands) Iain Wilson (Austria) to replace Leopold März Albert M. Wu (Taiwan) Lode Wyns (Belgium) Yehiel Zick (Israel) Glycoconj J (2011) 28: 197–369 Past Presidents Eugene. A. Davidson (USA) Alan B. Foster (UK) Paul Gleeson (Australia) Mary Catherine Glick (USA) Colin Hughes (UK) Roger W. -
Fiendish Designs
Fiendish Designs A Software Engineering Odyssey © Tim Denvir 2011 1 Preface These are notes, incomplete but extensive, for a book which I hope will give a personal view of the first forty years or so of Software Engineering. Whether the book will ever see the light of day, I am not sure. These notes have come, I realise, to be a memoir of my working life in SE. I want to capture not only the evolution of the technical discipline which is software engineering, but also the climate of social practice in the industry, which has changed hugely over time. To what extent, if at all, others will find this interesting, I have very little idea. I mention other, real people by name here and there. If anyone prefers me not to refer to them, or wishes to offer corrections on any item, they can email me (see Contact on Home Page). Introduction Everybody today encounters computers. There are computers inside petrol pumps, in cash tills, behind the dashboard instruments in modern cars, and in libraries, doctors’ surgeries and beside the dentist’s chair. A large proportion of people have personal computers in their homes and may use them at work, without having to be specialists in computing. Most people have at least some idea that computers contain software, lists of instructions which drive the computer and enable it to perform different tasks. The term “software engineering” wasn’t coined until 1968, at a NATO-funded conference, but the activity that it stands for had been carried out for at least ten years before that. -
Stem Cell Strategy by Establishing the Till & Mcculloch Medicines of Tomorrow Innovation Fund
A Pre-Budget Submission to the House of Commons Standing Committee on Finance To Implement the Canadian Stem Cell Strategy By Establishing The Till & McCulloch Medicines of Tomorrow Innovation Fund James Price President & CEO Canadian Stem Cell Foundation February 9, 2016 EXECUTIVE SUMMARY Stem cells represent the biggest innovation in medicine of the last half century. These cells have the power to cure many diseases for which current medical practice can only provide symptomatic relief and chronic care – a reality that is straining health care systems in Canada and in countries around the globe. Stem cells are a hallmark of Canadian innovation. They were first discovered in Canada and Canada is one of the top three countries in stem cell R&D, with our scientists ranking among the best in the world. Recent investments, such as the Government’s $20-million commitment to establish a cell-manufacturing facility in Toronto and the $114-million Medicine By Design grant for the University of Toronto, will help Canada move forward. However, major commitments by competitor jurisdictions – most notably California, with its investment of $3 billion, and Japan, with an investment of $1 billion in stem cells and regenerative medicine -- challenge Canada’s leadership in this sector of the knowledge economy. Moreover, Canada lacks a national plan to succeed in the coming cell therapy and regenerative medicine boom. The Canadian Stem Cell Strategy -- created in consultation with 150 scientists, medical doctors, leaders from major health charities, industry experts, investors and philanthropists – will: • deliver up to 10 new curative therapies within 10 years; • transform health care and ease the strain on the health system; and • attract private investment and generate 12,000 jobs for Canadians. -
Phosphorus Lewis Acids: Emerging Reactivity and Applications in Catalysis
Chemical Society Reviews Phosphorus Lewis Acids: Emerging Reactivity and Applications in Catalysis Journal: Chemical Society Reviews Manuscript ID: CS-REV-06-2015-000516.R1 Article Type: Tutorial Review Date Submitted by the Author: 30-Jul-2015 Complete List of Authors: Bayne, Julia; University of Toronto, Chemistry Stephan, Douglas; University of Toronto, Department of Chemistry Page 1 of 10 ChemicalPlease do notSociety adjust Reviews margins Journal Name ARTICLE Phosphorus Lewis Acids: Emerging Reactivity and Applications in Catalysis a a* Received 00th January 20xx, J. M. Bayne and D. W. Stephan Accepted 00th January 20xx Part of the renaissance in main group chemistry has been a result of the focus on reactivity. This has led to the DOI: 10.1039/x0xx00000x development of applications in stoichiometric reactivity and catalysis. In this tutorial review, we focus attention on the role of phosphorus-based Lewis acids in such advances. While early literature recognizes the role of P(III) and P(V) www.rsc.org/ electrophiles in coordination chemistry, it has generally been more recent studies that have focused on applications of this Lewis acidity. Applications of these novel P-based Lewis acids in stoichiometric reactivity, Lewis acid catalysis and frustrated Lewis pair (FLP) reactivity are reviewed. These advances demonstrate that P-based Lewis acids are a powerful tool for further developments in metal-free catalysis. Key Learning Points 1. The development of main group catalysis has contributed to significant advancements in catalytic and stoichiometric transformations. 2. Although P(III) species are typical Lewis bases, phosphenium cations have demonstrated electron accepting abilities. 3. As saturated acceptors, phosphorus(V)-based Lewis acids derive their acidity from a low lying σ* orbital. -
2019 Impact Report
2019 IMPACT REPORT Honouring Excellence. Preserving History. Inspiring Generations. We invite you to be inspired. FROM OUR BOARD CHAIR AND EXECUTIVE DIRECTOR It is an exciting time at the CMHF as we advance our mission thanks to vital and MISSION meaningful partnerships at many levels and the impacts of our programs in our 25th year of service are detailed well on the pages that follow. We are encouraged that our Recognize and celebrate capacity to do more going forward was strengthened this year with significant partner Canadian heroes whose investments: substantial operational support from the Canadian Medical Association work has advanced (CMA) for three years commencing in 2020 and program support from MD Financial health; inspire the Management across all our programs, including the Discovery Days in Health Sciences pursuit of careers in national presenting sponsorship. the health sciences. Change was also a theme for us in 2019 and it came in many forms: • After 16 years, we transitioned to temporary space at 100 Kellogg Lane in London, VISION ON in anticipation of developing our new Exhibit Hall space and offices in the North A Canada that honours Tower in 2020. This exciting, interactive destination will be home to the Children’s our medical heroes – Museum, an indoor adventure park, retail markets, a boutique hotel and an active those of the past, outdoor courtyard to name a few; an amazing co-location model that means more present and future. guests will experience the sense of pride we know comes with exploring our physical Laureate displays. • We undertook a review of our corporate identity and unveiled a new and contemporary brand, look and feel across all our programs.